FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer

FDA has approved the combination of two immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), as an initial treatment for some patients with advanced kidney cancer. Learn how this approval will affect patient care.

from Cancer via ola Kala on Inoreader https://ift.tt/2KPIxXG
via IFTTT